Cargando…

Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) involving a major branch of the portal or hepatic vein is in a locally advanced stage and remains difficult to cure. This study aimed to evaluate the clinical effects of carbon ion radiotherapy (C-ion RT) in locally advanced HCC (LAHCC). METHODS: The data o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiba, Shintaro, Shibuya, Kei, Okamoto, Masahiko, Okazaki, Shohei, Komatsu, Shuichiro, Kubota, Yoshiki, Nakano, Takashi, Ohno, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427730/
https://www.ncbi.nlm.nih.gov/pubmed/32795340
http://dx.doi.org/10.1186/s13014-020-01634-z
_version_ 1783570937078087680
author Shiba, Shintaro
Shibuya, Kei
Okamoto, Masahiko
Okazaki, Shohei
Komatsu, Shuichiro
Kubota, Yoshiki
Nakano, Takashi
Ohno, Tatsuya
author_facet Shiba, Shintaro
Shibuya, Kei
Okamoto, Masahiko
Okazaki, Shohei
Komatsu, Shuichiro
Kubota, Yoshiki
Nakano, Takashi
Ohno, Tatsuya
author_sort Shiba, Shintaro
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) involving a major branch of the portal or hepatic vein is in a locally advanced stage and remains difficult to cure. This study aimed to evaluate the clinical effects of carbon ion radiotherapy (C-ion RT) in locally advanced HCC (LAHCC). METHODS: The data of 11 consecutive patients with LAHCC who received C-ion RT were analyzed. The C-ion RT doses of 52.8 Gy (relative biological effectiveness [RBE]) and 60.0 Gy (RBE) were delivered in 4 fractions for standard cases, and the 60.0 Gy dose was delivered in 12 fractions for close-to-gastrointestinal-tract cases. Survival and local control probabilities were calculated using the Kaplan-Meier method. RESULTS: The median follow-up duration after C-ion RT was 36.4 months. The median age at the time of registration for C-ion RT was 76 years. The median tumor size was 53 mm. The numbers of treatment-naive and recurrent HCC patients were 1 and 10, respectively. Direct invasion of the major branch of the portal vein, hepatic vein, or both portal and hepatic veins was observed in three, five, and three patients, respectively. The 3-year overall survival, local control, and progression-free survival rates were 64, 78, and 18%, respectively. No patient developed radiation-induced liver diseases or grade 3 or higher toxicities in the acute and late phases. CONCLUSIONS: C-ion RT showed favorable clinical outcomes with a high rate of local control and minimal toxicities in LAHCC. Our findings suggest that C-ion RT is a promising multidisciplinary treatment option in LAHCC.
format Online
Article
Text
id pubmed-7427730
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74277302020-08-17 Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma Shiba, Shintaro Shibuya, Kei Okamoto, Masahiko Okazaki, Shohei Komatsu, Shuichiro Kubota, Yoshiki Nakano, Takashi Ohno, Tatsuya Radiat Oncol Research BACKGROUND: Hepatocellular carcinoma (HCC) involving a major branch of the portal or hepatic vein is in a locally advanced stage and remains difficult to cure. This study aimed to evaluate the clinical effects of carbon ion radiotherapy (C-ion RT) in locally advanced HCC (LAHCC). METHODS: The data of 11 consecutive patients with LAHCC who received C-ion RT were analyzed. The C-ion RT doses of 52.8 Gy (relative biological effectiveness [RBE]) and 60.0 Gy (RBE) were delivered in 4 fractions for standard cases, and the 60.0 Gy dose was delivered in 12 fractions for close-to-gastrointestinal-tract cases. Survival and local control probabilities were calculated using the Kaplan-Meier method. RESULTS: The median follow-up duration after C-ion RT was 36.4 months. The median age at the time of registration for C-ion RT was 76 years. The median tumor size was 53 mm. The numbers of treatment-naive and recurrent HCC patients were 1 and 10, respectively. Direct invasion of the major branch of the portal vein, hepatic vein, or both portal and hepatic veins was observed in three, five, and three patients, respectively. The 3-year overall survival, local control, and progression-free survival rates were 64, 78, and 18%, respectively. No patient developed radiation-induced liver diseases or grade 3 or higher toxicities in the acute and late phases. CONCLUSIONS: C-ion RT showed favorable clinical outcomes with a high rate of local control and minimal toxicities in LAHCC. Our findings suggest that C-ion RT is a promising multidisciplinary treatment option in LAHCC. BioMed Central 2020-08-14 /pmc/articles/PMC7427730/ /pubmed/32795340 http://dx.doi.org/10.1186/s13014-020-01634-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shiba, Shintaro
Shibuya, Kei
Okamoto, Masahiko
Okazaki, Shohei
Komatsu, Shuichiro
Kubota, Yoshiki
Nakano, Takashi
Ohno, Tatsuya
Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
title Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
title_full Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
title_fullStr Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
title_full_unstemmed Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
title_short Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
title_sort clinical impact of hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427730/
https://www.ncbi.nlm.nih.gov/pubmed/32795340
http://dx.doi.org/10.1186/s13014-020-01634-z
work_keys_str_mv AT shibashintaro clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT shibuyakei clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT okamotomasahiko clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT okazakishohei clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT komatsushuichiro clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT kubotayoshiki clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT nakanotakashi clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma
AT ohnotatsuya clinicalimpactofhypofractionatedcarbonionradiotherapyonlocallyadvancedhepatocellularcarcinoma